Jon Faiz Kayyem bought $997k of INBX
director at Inhibrx Biosciences, Inc.. 57,549 shares at an average of $17.32, traded Jun 5, 2024, filed Jun 7, 2024.
Score components
- +15RoleDirector
- +25Trade size$997k at market
- +3Relative to holdingsHoldings up 5%
- 0Price contextNear the top of the 52-week range
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -22.6%, 3m -9.6%, 6m -5.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002007919-24-000008, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 5, 2024 | POpen-market purchase Common Stockindirect: By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust | +49,284 | $17.23 | $849k | 1,142,145 | Jun 7, 2024 |
| Jun 5, 2024 | POpen-market purchase Common Stockindirect: By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust | +8,265 | $17.89 | $148k | 1,150,410 | Jun 7, 2024 |
Related signals
Other insiders at Inhibrx Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 21, 2026 | INBXbuy Inhibrx Biosciences, Inc. | Mark Lappe Chief Executive Officer | $849k 10,040 shares | +1% | |
| 63Notable | Inhibrx Biosciences, Inc. | Mark Lappe Chief Executive Officer | $999k 10,000 shares | +1% | |
| 46Moderate | Inhibrx Biosciences, Inc. | Jon Faiz Kayyem director | $500k 5,000 shares | +1% | |
| 53Moderate | Inhibrx Biosciences, Inc. | Jon Faiz Kayyem director | $500k 5,000 shares | +1% | |
| 31Weak | INBXsell Inhibrx Biosciences, Inc. | Kimberly Manhard director | $164k 1,500 shares | -17% | |
| 30Weak | INBXsell Inhibrx Biosciences, Inc. | Kimberly Manhard director | $115k 1,000 shares | -10% | |
| 44Moderate | Inhibrx Biosciences, Inc. | Douglas Forsyth director | $287k 2,500 shares | +1% | |
| 65Notable | Inhibrx Biosciences, Inc. | Mark Lappe Chief Executive Officer | $2.6M 25,000 shares | +4% | |
| 49Moderate | Inhibrx Biosciences, Inc. | Jon Faiz Kayyem director | $568k 5,000 shares | +1% | |
| 42Moderate | INBXsell Inhibrx Biosciences, Inc. | Viking Global Investors LP owner | $11M 350,000 shares | -22% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.